amcenestrant
Jump to navigation
Jump to search
Indications
- neoadjuvant therapy for estrogen receptor-positive, HER2-negative breast cancer
Dosage
- 200 mg, 400 mg PO
Mechanism of action
- antagonizes & degrades estrogen receptors
More general terms
References
- ↑ Shapiro M AMEERA-4: Neoadjuvant Amcenestrant vs Letrozole in Postmenopausal ER+/HER2- Breast Cancer Clinical Advances in Breast Cancer. June 30, 2022 https://www.mdalert.com/ms/cabreast/article/neoadjuvant-amcenestrant-vs-letrozole